This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Loss of fragile histidine triad protein expression and its clinicopathological significance in gastric cancer
Po Zhao, Wu Liu, Ya-Li Lu
Po Zhao, Wu Liu, Yali Lu, Department of Pathology, Chinese PLA General Hospital, Beijing 100853, China
Correspondence to: Po Zhao, Department of Pathology, Chinese PLA General Hospital, Beijing 100853, China. zhaopo@plagh.com.cn
Received: October 9, 2003 Revised: October 20, 2003 Accepted: November 13, 2003 Published online: March 15, 2004
AIM: To investigate the expression of fragile histidine triad protein, Fhit and the possible relationship between its expression and clinicopathological indices in gastric carcinoma.
METHODS: Fhit protein expression was detected in 76 cases of gastric carcinoma, 58 dysplasia and 10 normal mucosae by immunohistochemical method to analyse its relationship to histological grade, clinical stage, metastatic status and prognosis.
RESULTS: The loss of Fhit protein expression was detected in 48/76 (63.2%) cases of cancer tissue, 36/58 (62.1%)cases of adjacent dysplastic tissue and 0/10 cases of normal gastric mucosa. There was a significant difference in the expression of Fhit protein between cancer or adjacent dysplastic tissue and normal gastric mucosa (P=0.000). It was also showed that loss of Fhit protein expression was found first in 35.7% (10/28) of grade I-II, and in 79.2% (38/48) of grade III (P = 0.000); second in 43.8% (14/32)of stage I-II, whereas in 77.3% (34/44) of stage III-IV (P = 0.004); and last in 36.4% (8/22) of tumors without metastasis but in 74.1% (40/54) of those with metastasis (P = 0.003). The significant difference in the loss of expression of Fhit was found between cancers on different histological grade, clinical stage and metastatic status, respectively. Follow-up data showed that there was a significant difference in median survival time between carcinomas with loss of Fhit (33 mos) and those without (71 mos) (Log rank = 20.78; P = 0.000).
CONCLUSION: Fhit protein is an important tumor suppressor protein. Loss of Fhit protein expression may be associated with carcinogenesis, invasion, metastasis and prognosis in gastric carcinoma.
Key Words: N/A
Citation: Zhao P, Liu W, Lu YL. Loss of fragile histidine triad protein expression and its clinicopathological significance in gastric cancer. Shijie Huaren Xiaohua Zazhi 2004; 12(3): 516-519
Pekarsky Y, Zanesi N, Palamarchuk A, Huebner K, Croce CM. FHIT: from gene discovery to cancer treatment and prevention.Lancet Oncol. 2002;3:748-754.
[PubMed] [DOI]
Ginestier C, Bardou VJ, Popovici C, Charafe-Jauffret E, Bertucci F, Geneix J, Adélaïde J, Chaffanet M, Hassoun J, Viens P. Loss of FHIT protein expression is a marker of adverse evolution in good prognosis localized breast cancer.Int J Cancer. 2003;107:854-862.
[PubMed] [DOI]
Koda M, Yashima K, Kawaguchi K, Andachi H, Hosoda A, Shiota G, Ito H, Murawaki Y. Expression of Fhit, Mlh1, and P53 protein in human gallbladder carcinoma.Cancer Lett. 2003;199:131-138.
[PubMed] [DOI]
Yura Y, Mandai M, Konishi I, Hamid AA, Tsuruta Y, Kusakari T, Fujii S. Loss of Fhit protein expression in high-grade and advanced stage endometrial carcinomas.Anticancer Res. 2003;23:2837-2843.
[PubMed] [DOI]
Gopalakrishnan VK, Banerjee AG, Vishwanatha JK. Effect of FHIT gene replacement on growth, cell cycle and apoptosis in pancreatic cancer cells.Pancreatology. 2003;3:293-302.
[PubMed] [DOI]
Koch E, Fiedler W, Tannapfel A, Ballhausen WG. Alteration of the fragile histidine triad gene in intrahepatic cholangiocarcinoma.Eur J Gastroenterol Hepatol. 2003;15:907-913.
[PubMed] [DOI]
Machida S, Ohwada M, Saga Y, Suzuki M. Abnormal fragile histidine triad expression in advanced cervical cancer and evaluation of its utility as a prognostic factor.Oncology. 2003;65:89-93.
[PubMed] [DOI]
Zhao P, Song X, Nin YY, Lu YL, Li XH. Loss of fragile histidine triad protein in human hepatocellular carcinoma.World J Gastroenterol. 2003;9:1216-1219.
[PubMed] [DOI]
Lee HS, Lee HK, Kim HS, Yang HK, Kim WH. Tumour suppressor gene expression correlates with gastric cancer prognosis.J Pathol. 2003;200:39-46.
[PubMed] [DOI]
Rocco A, Schandl L, Chen J, Wang H, Tulassay Z, McNamara D, Malfertheiner P, Ebert MP. Loss of FHIT protein expression correlates with disease progression and poor differentiation in gastric cancer.J Cancer Res Clin Oncol. 2003;129:84-88.
[PubMed] [DOI]
Baykal C, Ayhan A, Al A, Yüce K, Ayhan A. No relationship is indicated between FHIT expression and clinicopathologic prognostic parameters in early stage cervical carcinoma.Int J Gynecol Cancer. 2003;13:192-196.
[PubMed] [DOI]
Sevignani C, Calin GA, Cesari R, Sarti M, Ishii H, Yendamuri S, Vecchione A, Trapasso F, Croce CM. Restoration of fragile histidine triad (FHIT) expression induces apoptosis and suppresses tumorigenicity in breast cancer cell lines.Cancer Res. 2003;63:1183-1187.
[PubMed] [DOI]
Sükösd F, Kuroda N, Beothe T, Kaur AP, Kovacs G. Deletion of chromosome 3p14.2-p25 involving the VHL and FHIT genes in conventional renal cell carcinoma.Cancer Res. 2003;63:455-457.
[PubMed] [DOI]
Petursdottir TE, Hafsteinsdottir SH, Jonasson JG, Moller PH, Thorsteinsdottir U, Huiping C, Egilsson V, Ingvarsson S. Loss of heterozygosity at the FHIT gene in different solid human tumours and its association with survival in colorectal cancer patients.Anticancer Res. 2002;22:3205-3212.
[PubMed] [DOI]
Mineta H, Miura K, Takebayashi S, Misawa K, Ueda Y, Suzuki I, Ito M, Wennerberg J. Low expression of fragile histidine triad gene correlates with high proliferation in head and neck squamous cell carcinoma.Oral Oncol. 2003;39:56-63.
[PubMed] [DOI]
Pekarsky Y, Palamarchuk A, Huebner K, Croce CM. FHIT as tumor suppressor: mechanisms and therapeutic opportunities.Cancer Biol Ther. 2002;1:232-236.
[PubMed] [DOI]
Zhao P, Lu Y, Hu Y, Zhong M, Li Z, Li X. Loss of fragile histidine triad expression in colorectal carcinoma.Zhonghua Bing Li Xue Za Zhi. 2002;31:124-127.
[PubMed] [DOI]
Chang YT, Wu MS, Chang CJ, Huang PH, Hsu SM, Lin JT. Preferential loss of Fhit expression in signet-ring cell and Krukenberg subtypes of gastric cancer.Lab Invest. 2002;82:1201-1208.
[PubMed] [DOI]
Petursdottir TE, Hafsteinsdottir SH, Jonasson JG, Moller PH, Thorsteinsdottir U, Huiping C, Egilsson V, Ingvarsson S. Loss of heterozygosity at the FHIT gene in different solid human tumours and its association with survival in colorectal cancer patients.Anticancer Res. 2002;22:3205-3212.
[PubMed] [DOI]
Mady HH, Melhem MF. FHIT protein expression and its relation to apoptosis, tumor histologic grade and prognosis in colorectal adenocarcinoma: an immunohistochemical and image analysis study.Clin Exp Metastasis. 2002;19:351-358.
[PubMed] [DOI]
Pavelić K, Krizanac S, Cacev T, Hadzija MP, Radosević S, Crnić I, Levanat S, Kapitanović S. Aberration of FHIT gene is associated with increased tumor proliferation and decreased apoptosis-clinical evidence in lung and head and neck carcinomas.Mol Med. 2001;7:442-453.
[PubMed] [DOI]
Mori M, Mimori K, Masuda T, Yoshinaga K, Yamashita K, Matsuyama A, Inoue H. Absence of Msh2 protein expression is associated with alteration in the FHIT locus and Fhit protein expression in colorectal carcinoma.Cancer Res. 2001;61:7379-7382.
[PubMed] [DOI]
Caselli M, Marchisio M, Gaudio M, Saragoni L, Lanza G, Alvisi V, Bertagnolo V, Concu M, Capitani S, Caramelli E. Fhit protein expression in human gastric cancer and related precancerous lesions.Oncol Rep. 2001;8:1233-1237.
[PubMed] [DOI]
Kitamura A, Yashima K, Okamoto E, Andachi H, Hosoda A, Kishimoto Y, Shiota G, Ito H, Kaibara N, Kawasaki H. Reduced Fhit expression occurs in the early stage of esophageal tumorigenesis: no correlation with p53 expression and apoptosis.Oncology. 2001;61:205-211.
[PubMed] [DOI]
Deng YF, Tian F, Lu YD, Chen ZC, Xie DH, Yang XM, Shao XY. Mutation and abnormal expression of the fragile histidine triad gene in nasopharyngeal carcinoma.Laryngoscope. 2001;111:1589-1592.
[PubMed] [DOI]